Advances on the role of pegaspargase in the treatment of childhood leukemia.
- Author:
Li LIU
1
;
Xiao-Tian XIE
Author Information
1. Department of Pediatrics, Tongji Hospital, Tongji University, Shanghai 200065, China. xtxie@163.com.
- Publication Type:Journal Article
- MeSH:
Antineoplastic Agents;
therapeutic use;
Asparaginase;
adverse effects;
pharmacokinetics;
pharmacology;
therapeutic use;
Blood Coagulation Disorders;
chemically induced;
Humans;
Pancreatitis;
chemically induced;
Polyethylene Glycols;
adverse effects;
pharmacokinetics;
pharmacology;
therapeutic use;
Precursor Cell Lymphoblastic Leukemia-Lymphoma;
drug therapy
- From:
Chinese Journal of Contemporary Pediatrics
2014;16(2):155-160
- CountryChina
- Language:Chinese
-
Abstract:
The chemotherapy agent L-asparaginase (L-asp) has been an important part of acute lymphoblastic leukemia therapy for over 30 years. It is evident that L-asp has a long-term curative effect. However, L-asp is associated with high incidence of adverse reactions. This has prompted the development of pegylated asparaginase (PEG-asp), which has undergone extensive testing. Apparently, PEG-asp has a prolonged half-life with a better tolerance profile while retaining the antileukemic effect. In this review, we attempt to outline the history of clinical application of L-asp, the pharmacological and clinical potential of various preparations of L-asp, the development of PEG-asp, and the clinical application and adverse events of PEG-asp. The literatures reviewed in this article is collected through online search of the major databases both in English and Chinese.
